US 12,263,325 B2
Device, system and methods for the oral delivery of therapeutic compounds
Mir Imran, Los Altos Hills, CA (US); Peter Herrmann, San Jose, CA (US); Baber Syed, Palo Alto, CA (US); Timothy H. Williams, Campbell, CA (US); Chang Jin Ong, Fremont, CA (US); and Greg Method, San Jose, CA (US)
Assigned to Rani Therapeutics, LLC, San Jose, CA (US)
Filed by Rani Therapeutics, LLC, San Jose, CA (US)
Filed on Oct. 5, 2023, as Appl. No. 18/481,857.
Application 18/481,857 is a continuation of application No. 16/828,914, filed on Mar. 24, 2020, granted, now 11,806,504.
Application 16/828,914 is a continuation of application No. 15/674,421, filed on Aug. 10, 2017, granted, now 10,632,251.
Application 15/674,421 is a continuation of application No. 14/244,673, filed on Apr. 3, 2014, granted, now 9,757,514.
Application 14/244,673 is a continuation of application No. 13/837,025, filed on Mar. 15, 2013, granted, now 8,734,429.
Application 13/837,025 is a continuation in part of application No. 13/532,589, filed on Jun. 25, 2012, granted, now 9,149,617.
Application 13/532,589 is a continuation in part of application No. 12/978,301, filed on Dec. 23, 2010, granted, now 8,562,589.
Application 13/532,589 is a continuation in part of application No. 12/978,233, filed on Dec. 23, 2010, granted, now 8,721,620.
Claims priority of provisional application 61/571,641, filed on Jun. 29, 2011.
Prior Publication US 2024/0082488 A1, Mar. 14, 2024
Int. Cl. A61M 5/155 (2006.01); A61K 38/13 (2006.01); A61K 38/21 (2006.01); A61K 38/26 (2006.01); A61K 38/27 (2006.01); A61K 38/28 (2006.01); A61K 38/29 (2006.01); A61K 38/30 (2006.01); A61K 38/55 (2006.01); A61M 5/142 (2006.01); A61M 31/00 (2006.01); A61K 9/48 (2006.01); A61M 37/00 (2006.01)
CPC A61M 5/155 (2013.01) [A61K 38/13 (2013.01); A61K 38/21 (2013.01); A61K 38/26 (2013.01); A61K 38/27 (2013.01); A61K 38/28 (2013.01); A61K 38/29 (2013.01); A61K 38/30 (2013.01); A61K 38/55 (2013.01); A61M 5/14244 (2013.01); A61M 31/002 (2013.01); A61K 9/4808 (2013.01); A61M 37/0069 (2013.01); A61M 2205/3331 (2013.01); A61M 2210/1042 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of delivering a therapeutic agent preparation into a gastrointestinal (GI) wall of a patient, the method comprising:
administering, by swallowing by a patient, a swallowable device sized to pass through a GI tract, wherein the device comprises a capsule, the therapeutic agent preparation disposed within the capsule, an aligner, and a delivery mechanism for advancing the therapeutic agent preparation from the capsule into the GI wall, wherein the delivery mechanism comprises an expandable member and a piston-cylinder assembly operably coupled to the expandable member, wherein the piston-cylinder assembly comprises a piston slidably disposed in a cylinder, and wherein the piston-cylinder assembly is at least partially disposed in the expandable member;
wherein, upon swallowing of the device, the piston-cylinder assembly is oriented relative to the GI wall via the aligner such that a long axis of the piston-cylinder assembly is perpendicular to a surface of the GI wall; and
wherein the expandable member causes the piston to advance through the cylinder to deliver the therapeutic agent preparation into the GI wall.